Molecular Imaging

Catch up on the most well-viewed video interviews from Diagnostic Imaging in 2024.

Touching on a variety of topics in radiology, here are the top five most well-viewed content from Diagnostic Imaging in 2024.

Catch up on the most well-viewed prostate imaging content from 2024.

Catch up on the most-well viewed radiology content in December 2024.

Catch up on the top AI-related news and research in radiology over the past month.

Catch up on the most well-read mammography articles from 2024.

Catch up on the top radiology content of the past week.

Catch up on the top radiology content of the past week.

Catch up on the most-well viewed radiology content in November 2024.

Catch up on the top radiology content of the past week.

Catch up on the top radiology content of the past week.

Catch up on the top radiology content of the past week.

Examining six comparative studies within a new meta-analysis, researchers found that FAPI PET/CT offered 11 percent higher pooled sensitivity and 28 percent higher pooled specificity than FDG PET/CT for diagnosing lymph node metastases in patients with lung cancer.

Catch up on the top radiology content of the past week.

Catch up on the top radiology content of the past week.

The clearance may facilitate improved standardization and efficiency of dosimetry-guided, theranostic applications of radiopharmaceutical therapy.

Catch up on the top radiology content of the past week.

Offering higher diagnostic efficacy than SPECT imaging for coronary artery disease (CAD) detection, the PET myocardial perfusion imaging agent Flyrcado™ (flurpiridaz F 18, GE HealthCare) provides unit dose availability and effectiveness in imaging patients with high BMI.

Catch up on the most-well viewed radiology content in September 2024.

Catch up on the most-well viewed prostate imaging content in September 2024.

Catch up on the top radiology content of the past week.

Now available with MIMneuro, the Centiloid scaling software provides automated quantitative assessment of amyloid plaque density, a key component of Alzheimer’s disease.

Catch up on the top radiology content of the past week.

Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.

The imaging agent 18F-FAPI PET/CT demonstrated greater than a 45 percent higher sensitivity rate in comparison to 18F-FDG PET/CT for the detection of axillary and extraaxillary regional lymph node metastases, according to a lesion-based analysis from a recent study.

Catch up on the most-well viewed radiology content in August 2024.

Targeting tau neurofibrillary tangles, the (18F)PI-2620 agent reportedly provides promising insight into the development of three neurodegenerative conditions including Alzheimer’s disease.

Catch up on the top radiology content of the past week.

Catch up on the top radiology content of the past week.

Reportedly the only imaging agent to garner a breakthrough therapy designation for cardiac amyloidosis, 124I-evuzamitide has demonstrated robust sensitivity for the condition as well as a favorable safety profile.